Novel [(N-alkyl-3-indolylmethylene)hydrazono]oxindoles arrest cell cycle and induce cell apoptosis by inhibiting CDK2 and Bcl-2: synthesis, biological evaluation and in silico studies

Journal of Enzyme Inhibition and Medicinal Chemistry

Hatem A. Abdel-Aziz¹  Hadia Almahli²  Ohoud J. Alotaibi³  Tarfah Al-Warhi³  Mohammad M. Al-Sanea⁴  Mahmoud F. Abo-Ashour⁵  Wagdy M. Eldehna⁶  Ghada H. Al-Ansary⁷  Mahmoud M. Elaasser⁸  Hanaa Y. Ahmed⁸ 

[1] Department of Applied Organic Chemistry, National Research Center;Department of Chemistry, Chemistry Research Laboratory, University of Oxford;Department of Chemistry, College of Science, Princess Nourah bint Abdulrahman University;Department of Pharmaceutical Chemistry, College of Pharmacy, Jouf University;Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Egyptian Russian University;Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University;Department of Pharmaceutical Chemistry, Pharmacy Program, Batterejee Medical College;The Regional Center for Mycology and Biotechnology, Al-Azhar University;

关键词: isatin;    n-alkylindole;    hybridisation;    anticancer;    bcl-2 inhibitor;    cdk2 inhibitor;   

DOI  :  10.1080/14756366.2020.1773814

来源: DOAJ

【 摘 要 】

As a continuation for our previous work, a novel set of N-alkylindole-isatin conjugates (7, 8a–c, 9 and 10a–e) is here designed and synthesised with the prime aim to develop more efficient isatin-based antitumor candidates. Utilising the SAR outputs from the previous study, our design here is based on appending four alkyl groups with different length (ethyl and n-propyl), bulkiness (iso-propyl) and unsaturation (allyl) on N-1 of indole motif, with subsequent conjugation with different N-unsubstituted isatin moieties to furnish the target conjugates. As planned, the adopted strategy achieved a substantial improvement in the growth inhibitory profile for the target conjugates in comparison to the reported lead VI. The best results were obtained with N-propylindole –5-methylisatin hybrid 8a which displayed broad spectrum anti-proliferative action with efficient sub-panel GI50 (MG-MID) range from 1.33 to 4.23 µM, and promising full-panel GI50 (MG-MID) equals 3.10 µM, at the NCI five-dose assay. Also, hybrid 8a was able to provoke cell cycle disturbance and apoptosis in breast T-47D cells as evidenced by the DNA flow cytometry and Annexin V-FITC/PI assays. Furthermore, hybrid 8a exhibited good inhibitory action against cell cycle regulator CDK2 protein kinase and the anti-apoptotic Bcl-2 protein (IC50= 0.85 ± 0.03 and 0.46 ± 0.02 µM, respectively). Interestingly, molecular docking for hybrid 8a in CDK2 and Bcl-2 active sites unveiled that N-propyl group is involved in significant hydrophobic interactions. Taken together, the results suggested conjugate 8a as a promising lead for further development and optimisation as an efficient antitumor drug.

【 授权许可】

Unknown